Thus, these mutations may play a role in resistance of a subset of BRAF mutated cancers to targeted therapies, through the extensive crosstalk of the KRAS/RAF/MEK/ERK and the PI3K/AKT/mTOR pathways [13,14]. This evidence concerns the gene MTOR and cancer.